The citrullinemia market is experiencing steady growth due to advancements in diagnostic techniques, increasing research on genetic disorders, and the rising prevalence of rare metabolic diseases. Citrullinemia, a genetic disorder caused by a deficiency in the enzyme argininosuccinate synthetase, results in the accumulation of toxic substances in the blood, leading to severe health complications. Early diagnosis and treatment are crucial in managing the disease, driving the demand for advanced diagnostic tools, such as genetic testing and newborn screening. Recent developments in gene therapy and enzyme replacement therapy (ERT) have opened new avenues for treatment, with research focusing on innovative solutions to manage or potentially cure citrullinemia. Companies are also exploring therapies to address ammonia toxicity and improve patient outcomes. For instance, the development of small molecules and amino acid-based supplements is being investigated to help manage symptoms. The market is further driven by the increasing government and healthcare support in both developed and emerging regions, leading to improved access to treatments. With rising awareness about metabolic diseases and advancements in biotechnology, the citrullinemia market is expected to see significant growth, with better therapeutic options and diagnostic tools becoming more accessible to patients worldwide.
